<DOC>
	<DOCNO>NCT02867020</DOCNO>
	<brief_summary>Evaluation activity , safety patient report outcome ADT plus abiraterone , abiraterone plus APALUTAMIDE ( second-generation antiandrogen ) APALUTAMIDE alone hormone naïve locally advanced metastatic prostate cancer ADT indicate .</brief_summary>
	<brief_title>Study Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone APALUTAMIDE Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels</brief_title>
	<detailed_description>Based current guideline , ADT alone combine antiandrogens consider appropriate active therapy patient population plan study . Recent data show chemotherapy also benefit patient set . Even though , clear unmet medical need alternative treatment option metastatic hormone sensitive prostate cancer ( mHSPC ) . Treatments delay disease progression , associate less comorbidities would significant clinical benefit patient population . The study design assess efficacy safety abiraterone plus APALUTAMIDE ( second-generation antiandrogen ) APALUTAMIDE alone without castration side effect arm combination ADT abiraterone ; last arm reflect Abiraterone ongoing pivotal trial ( LATITUDE ) , assess efficacy add abiraterone castration set patient . Abiraterone already show clinical benefit CRPC patient without prior chemotherapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>1 . Histologically confirm prostate adenocarcinoma ; 2 . Hormone naïve patient indication ADT follow setting : Advanced locoregional disease amenable curative local therapy ( surgery radiotherapy ) : T category T3/4 node positive Biochemical relapse primary treatment ( surgery radiotherapy ) : patient primary therapy appropriate feasible Previously treat radical surgery and/or radiotherapy , relapse least one criterion : PSA &gt; = 4 ng/ml rise double time le 10 month . PSA &gt; = 20 ng/ml N+ M+ Newly diagnose metastatic disease : Tany Nany M+ 3 . Patient asymptomatic moderately symptomatic regard bone symptom , i.e. , need palliative radiation radionuclide therapy ; 4 . Noncastration level testosterone &gt; 230ng/dL ( &gt; 8 nmol/L ) ; 5 . Baseline level prostatespecific antigen ( PSA ) &gt; 2ng/dL ; 6 . ECOG performance status 0 2 ; 7 . Adequate hematologic , hepatic renal function : 1. hemoglobin &gt; 10 g/dL , neutrophils &gt; 1.5×109 / L , platelets &gt; 100×109 / L ; 2. total bilirubin &lt; 1.5x upper limit normal ( ULN ) ; alanine ( ALT ) aspartate ( AST ) aminotransferase &lt; 2.5 x ULN ; 3. serum creatinine &lt; 1.5x ULN ; potassium &gt; 3.5 mM ; 8 . No previous cancer ( except treat basalcell skin cancer ) ; 9 . Written inform consent obtain prior study procedure ; 10 . Men age 18 year old ; 11 . Agrees use condom another effective method birth control sex woman childbearing potential agrees use condom sex woman pregnant . 1 . Prostate adenocarcinoma neuroendocrine differentiation small cell histology ; 2 . Biochemical recurrence without evidence clinical radiological disease ; 3 . Use hormonal therapy chemotherapy prior randomization . Exception course hormone therapy localise disease must complete least 12 month previously . It give adjuvant neoadjuvant therapy . 4 . Prior radiation therapy primary tumour within 3 month enrollment treatment metastasis ; 5 . Known suspected brain skull metastasis leptomeningeal metastatic disease ; 6 . Any concurrent severe and/or uncontrolled medical condition could compromise participation study ; 7 . Administration investigational therapeutic invasive surgical procedure ( include surgical castration ) within 28 day Cycle 1 Day 1 currently enrol investigational study ; 8 . Active symptomatic viral hepatitis chronic liver disease ; ascites bleed disorder secondary hepatic dysfunction ; 9 . Current prior treatment antiepileptic medication treatment seizure ; 10 . Impaired cardiac function , include follow : 1 . Uncontrolled hypertension ( systolic blood pressure ≥160 mmHg diastolic BP ≥95 mmHg ) ; 2 . Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event history cardiac failure past 6 month , severe unstable angina , New York Heart Association ( NYHA ) Class IIIV heart disease ; 3 . Existing atrial fibrillation without pharmacotherapy . Other cardiac arrhythmia require pharmacotherapy ; 4 . History seizure condition may predispose seizure ( include , limited prior stroke , transient ischemic attack loss consciousness ≤1 year prior randomization ; brain arteriovenous malformation ; intracranial mass schwannomas meningiomas cause edema mass effect ) ; 11 . Specific underlying condition oral agent . For example : impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption abiraterone APALUTAMIDE ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) 12 . General exclude medication ( e.g. , relevant cytochrome P450 interaction ) 1 . Use prescription drug within 14 day prior dose overthecounter ( OTC ) medication within 7 day prior dose ; 2 . Consumption grapefruit product St John 's wort within 7 day prior dose ; 3 . GCSF , GMCSF , erythropoietin , etc ; 4 . Coumadin ; 5 . Drugs may cause QT prolongation ; 6 . Known sensitivity drug metabolites similar class ; 7 . Known suspected contraindication hypersensitivity APALUTAMIDE , bicalutamide GnRH agonists component formulation ; 13 . Any condition situation , opinion investigator , would put subject risk , may confound study result , interfere subject 's participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>apalutamide</keyword>
	<keyword>abiraterone</keyword>
	<keyword>prostate cancer</keyword>
</DOC>